|
|
 Previous Article | Table of Contents | Next Article 
Effect of aggressive daunomycin therapy on survival in acute promyelocytic
leukemia
D Head, KJ Kopecky, J Weick, JC Files, D Ryan, K Foucar, M Montiel, J Bickers, A Fishleder and M Miller
St Jude Children's Research Hospital, Memphis, TN, USA.
The Southwest Oncology Group analyzed outcome with cytotoxic chemotherapy
for previously untreated acute myeloblastic leukemia (AML) from 1982
through 1986. Results with acute promyelocytic leukemia (APL) prompted
comparison with patients from 1986 through 1991 and analysis of factors
contributing to APL results. Patient and disease characteristics and
treatment outcome were compared for all evaluable patients, with more
detailed analysis of factors affecting APL treatment outcome. From 1982
through 1986, median survival and disease- free survival in 45 APL patients
were 106 months and greater than 105 months, respectively, versus 6 and 14
months for 417 other AML patients. Such differences were not seen from 1986
through 1991. In the 141 APL patients from 1982 through 1991, after
adjusting for significant patient and disease characteristics, higher
daunomycin (DNR) doses during induction were significantly associated with
higher complete remission rates (P < .0001), longer survival (P <
.0001), and longer DFS (P < .0001). Cytosine arabinoside (Ara-C)
induction dose, the inclusion of other chemotherapy agents in induction,
postremission therapy (consolidation, maintenance, or bone marrow
transplantation) other than DNR, APL subtype, and patient age did not
appear to significantly affect outcome of APL, except for a significant
detrimental effect of high-dose Ara-C in consolidation (P = .0042).
Morphologic AML subtypes other than APL did not affect outcome. We conclude
that high-dose DNR selectively increases survival in APL. This good
survival is important for evaluation of combined all-trans retinoic acid
(ATRA)/chemotherapy protocols and for planning future combinations of
chemotherapy and ATRA. These results illustrate the need to individualize
chemotherapy for subtypes of AML. Therapeutic response of APL is
independent of age. Except for APL, morphologic subclassification of AML
contributed little prognostic information.
Volume 86,
Issue 5,
pp. 1717-1728,
09/01/1995
Copyright © 1995 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. Ades, M. A. Sanz, S. Chevret, P. Montesinos, P. Chevallier, E. Raffoux, E. Vellenga, A. Guerci, A. Pigneux, F. Huguet, et al.
Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results
Blood,
February 1, 2008;
111(3):
1078 - 1084.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Asou, Y. Kishimoto, H. Kiyoi, M. Okada, Y. Kawai, M. Tsuzuki, K. Horikawa, M. Matsuda, K. Shinagawa, T. Kobayashi, et al.
A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RAR{alpha} transcript after consolidation therapy: The Japan Adult Leukemia Study Group (JALSG) APL97 study
Blood,
July 1, 2007;
110(1):
59 - 66.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Ades, S. Chevret, E. Raffoux, S. de Botton, A. Guerci, A. Pigneux, A. M. Stoppa, T. Lamy, F. Rigal-Huguet, A. Vekhoff, et al.
Is Cytarabine Useful in the Treatment of Acute Promyelocytic Leukemia? Results of a Randomized Trial From the European Acute Promyelocytic Leukemia Group
J. Clin. Oncol.,
December 20, 2006;
24(36):
5703 - 5710.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Frankfurt and M. S. Tallman
Strategies for the Treatment of Acute Promyelocytic Leukemia
J Natl Compr Canc Netw,
January 1, 2006;
4(1):
37 - 50.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. E. Ross, R. Mahfouz, M. Onciu, H.-C. Liu, X. Zhou, G. Song, S. A. Shurtleff, S. Pounds, C. Cheng, J. Ma, et al.
Gene expression profiling of pediatric acute myelogenous leukemia
Blood,
December 1, 2004;
104(12):
3679 - 3687.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Y. Au, A. K. W. Lie, C. S. Chim, R. Liang, S. K. Ma, C. H. Chan, Y. K. Mak, Y. T. Chen, C. C. So, Y. M. Yeung, et al.
Arsenic trioxide in comparison with chemotherapy and bone marrow transplantation for the treatment of relapsed acute promyelocytic leukaemia
Ann. Onc.,
May 1, 2003;
14(5):
752 - 757.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Lowenberg, J. D. Griffin, and M. S. Tallman
Acute Myeloid Leukemia and Acute Promyelocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
82 - 101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, W. G. Woods, A. Ogden, H. Weinstein, L. Shepherd, C. Willman, et al.
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol
Blood,
December 15, 2002;
100(13):
4298 - 4302.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Avvisati, M. C. Petti, F. Lo-Coco, M. L. Vegna, S. Amadori, M. Baccarani, N. Cantore, E. Di Bona, F. Ferrara, G. Fioritoni, et al.
Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up
Blood,
October 16, 2002;
100(9):
3141 - 3146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, C. Nabhan, J. H. Feusner, and J. M. Rowe
Acute promyelocytic leukemia: evolving therapeutic strategies
Blood,
February 1, 2002;
99(3):
759 - 767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. J. Giles, A. Keating, A. H. Goldstone, I. Avivi, C. L. Willman, and H. M. Kantarjian
Acute Myeloid Leukemia
Hematology,
January 1, 2002;
2002(1):
73 - 110.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
N. Niitsu, Y. Ishii, A. Matsuda, and Y. Honma
Induction of Differentiation of Acute Promyelocytic Leukemia Cells by a Cytidine Deaminase-resistant Analogue of 1-{beta}-D-Arabinofuranosylcytosine, 1-(2-Deoxy-2-methylene-{beta}-D-erythro-pentofuranosyl)cytidine
Cancer Res.,
January 1, 2001;
61(1):
178 - 185.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
F. R. Appelbaum, J. M. Rowe, J. Radich, and J. E. Dick
Acute Myeloid Leukemia
Hematology,
January 1, 2001;
2001(1):
62 - 86.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. P. Leith, K. J. Kopecky, I-M. Chen, L. Eijdems, M. L. Slovak, T. S. McConnell, D. R. Head, J. Weick, M. R. Grever, F. R. Appelbaum, et al.
Frequency and Clinical Significance of the Expression of the Multidrug Resistance Proteins MDR1/P-Glycoprotein, MRP1, and LRP in Acute Myeloid Leukemia. A Southwest Oncology Group Study
Blood,
August 1, 1999;
94(3):
1086 - 1099.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. L. Coco, D. Diverio, B. Falini, A. Biondi, C. Nervi, and P. G. Pelicci
Genetic Diagnosis and Molecular Monitoring in the Management of Acute Promyelocytic Leukemia
Blood,
July 1, 1999;
94(1):
12 - 22.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Grimwade, H. Walker, F. Oliver, K. Wheatley, C. Harrison, G. Harrison, J. Rees, I. Hann, R. Stevens, A. Burnett, et al.
The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial
Blood,
October 1, 1998;
92(7):
2322 - 2333.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Ding, Y.-P. Li, L. M. Nobile, G. Grills, I. Carrera, E. Paietta, M. S. Tallman, P. H. Wiernik, and R. E. Gallagher
Leukemic Cellular Retinoic Acid Resistance and Missense Mutations in the PML-RARalpha Fusion Gene After Relapse of Acute Promyelocytic Leukemia From Treatment With All-trans Retinoic Acid and Intensive Chemotherapy
Blood,
August 15, 1998;
92(4):
1172 - 1183.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Estey, P. Thall, M. Beran, H. Kantarjian, S. Pierce, and M. Keating
Effect of Diagnosis (Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, or Acute Myeloid Leukemia [AML]) on Outcome of AML-Type Chemotherapy
Blood,
October 15, 1997;
90(8):
2969 - 2977.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. S. Tallman, J. W. Andersen, C. A. Schiffer, F. R. Appelbaum, J. H. Feusner, A. Ogden, L. Shepherd, C. Willman, C. D. Bloomfield, J. M. Rowe, et al.
All-trans-Retinoic Acid in Acute Promyelocytic Leukemia
N. Engl. J. Med.,
October 9, 1997;
337(15):
1021 - 1028.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Gallagher, C. L. Willman, J. L. Slack, J. W. Andersen, Y.-P. Li, D. Viswanatha, C. D. Bloomfield, F. R. Appelbaum, C. A. Schiffer, M. S. Tallman, et al.
Association of PML-RARalpha Fusion mRNA Type With Pretreatment Hematologic Characteristics But Not Treatment Outcome in Acute Promyelocytic Leukemia: An Intergroup Molecular Study
Blood,
August 15, 1997;
90(4):
1656 - 1663.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Mandelli, D. Diverio, G. Avvisati, A. Luciano, T. Barbui, C. Bernasconi, G. Broccia, R. Cerri, M. Falda, G. Fioritoni, et al.
Molecular Remission in PML/RARalpha -Positive Acute Promyelocytic Leukemia by Combined All-trans Retinoic Acid and Idarubicin (AIDA) Therapy
Blood,
August 1, 1997;
90(3):
1014 - 1021.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-P. Li, J. Andersen, A. Zelent, S. Rao, E. Paietta, M. S. Tallman, P. H. Wiernik, and R. E. Gallagher
RARalpha 1/RARalpha 2-PML mRNA Expression in Acute Promyelocytic Leukemia Cells: A Molecular and Laboratory-Clinical Correlative Study
Blood,
July 1, 1997;
90(1):
306 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. E. Banker, M. Groudine, T. Norwood, and F. R. Appelbaum
Measurement of Spontaneous and Therapeutic Agent-Induced Apoptosis With BCL-2 Protein Expression in Acute Myeloid Leukemia
Blood,
January 1, 1997;
89(1):
243 - 255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
